Gemina Laboratories Ltd. (GLABF)
PNK · Healthcare · Biotechnology
$0.05
+0.00%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$3.8M
Shares Outstanding
76.6M
P/S (TTM)
352x
Exchange
PNK
Currency
USD
About Gemina Laboratories Ltd.
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.
Quarterly Financials
| Metric | 2024-10-31 | 2025-01-31 | 2025-04-30 | 2025-10-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 11K | 0.00 |
| Operating Income | -822K | -1.4M | -693K | -335K |
| Net Income | -864K | -1.4M | -761K | -334K |
| Diluted EPS | $-0.01 | $nan | $-0.01 | $0.00 |
Annual Financials
| Metric | 2022-01-31 | 2023-01-31 | 2024-01-31 | 2025-01-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -4.7M | -6.0M | -5.2M | -3.9M |
| Net Income | -4.7M | -6.0M | -5.2M | -4.1M |
| Diluted EPS | $-0.10 | $-0.10 | $-0.07 | $-0.06 |